Development of small-molecule inhibitors targeting adipose triglyceride lipase

N. Mayer, M. Schweiger, M. Romauch, G.F. Grabner, T.O. Eichmann, E. Fuchs, J. Ivkovic, C. Heier, I. Mrak, A. Lass, G. Höfler, C. Fledelius, Rudolf Zechner, Robert Zimmermann*, R. Breinbauer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Adipose triglyceride lipase (ATGL) is rate limiting in the mobilization of fatty acids from cellular triglyceride stores. This central role in lipolysis marks ATGL as an interesting pharmacological target as deregulated fatty acid metabolism is closely linked to dyslipidemic and metabolic disorders. Here we report on the development and characterization of a small-molecule inhibitor of ATGL. Atglistatin is selective for ATGL and reduces fatty acid mobilization in vitro and in vivo
Original languageEnglish
Pages (from-to)785-787
JournalNature Chemical Biology
Publication statusPublished - 2013

Fields of Expertise

  • Human- & Biotechnology

Treatment code (Nähere Zuordnung)

  • My Favorites


  • BioTechMed-Graz


Dive into the research topics of 'Development of small-molecule inhibitors targeting adipose triglyceride lipase'. Together they form a unique fingerprint.

Cite this